PMID- 8732695
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20191101
IS  - 1067-5582 (Print)
IS  - 1067-5582 (Linking)
VI  - 19
IP  - 2
DP  - 1996 Mar
TI  - Treatment of oral cavity and oropharynx squamous cell carcinoma with 
      perilymphatic interleukin-2: clinical and pathologic correlations.
PG  - 125-33
AB  - We describe the correlations between the clinical and histologic findings in an 
      initial series of 60 patients with T2-4, N0-3, M0 squamous cell carcinoma (SCC) 
      of the oral cavity or oropharynx enrolled in a randomized trial set up to 
      evaluate whether the disease-free interval and survival are extended when 
      perilymphatic injections of recombinant interleukin-2 (rIL-2) are combined with 
      routine surgery and radiotherapy. Twenty-nine patients were operated on only 
      (controls). The other 31 received two daily injections of 2,500 U rIL-2, one near 
      the mastoid process on the same side as the tumor and the other under the chin, 
      for 10 days before surgery, and further injections on the nonoperated-on side on 
      a monthly basis for 1 year starting 4 weeks after surgery (or radiotherapy, where 
      necessary) in an effort to upregulate the immune system and delay recurrence. 
      Their surgical specimens displayed a significantly greater inflammatory reaction, 
      larger areas of necrosis, and more intense sclerosis. The inflammatory tumor 
      infiltration consisted of eosinophils, plasma cells, and CD25+ and human 
      leukocyte antigen (HLA)-DR+ lymphocytes. However, no correlations were apparent 
      with regard to the intensity of necrosis, eosinophil infiltration, and the number 
      of DR+ cells and the clinical outcome. By contrast, the correlation between CD25+ 
      cells and a significantly longer disease-free survival suggests that induction of 
      T-cell reactivity, and perhaps specific immunity, is the only important aspect of 
      rIL-2-induced antitumor reactivity.
FAU - De Stefani, A
AU  - De Stefani A
AD  - Department of Otolaryngology, University of Turin, Italy.
FAU - Valente, G
AU  - Valente G
FAU - Forni, G
AU  - Forni G
FAU - Lerda, W
AU  - Lerda W
FAU - Ragona, R
AU  - Ragona R
FAU - Cortesina, G
AU  - Cortesina G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother Emphasis Tumor Immunol
JT  - Journal of immunotherapy with emphasis on tumor immunology : official journal of 
      the Society for Biological Therapy
JID - 9418950
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/immunology/*therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunotherapy, Active
MH  - Interleukin-2/administration & dosage/*therapeutic use
MH  - Lymphatic System/immunology
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/immunology/*therapy
MH  - Oropharyngeal Neoplasms/immunology/*therapy
MH  - Recombinant Proteins/administration & dosage/*therapeutic use
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
AID - 10.1097/00002371-199603000-00005 [doi]
PST - ppublish
SO  - J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):125-33. doi: 
      10.1097/00002371-199603000-00005.